Last updated: 4 December 2018 at 5:06pm EST

Kevin Ctang Capital Partner... Net Worth




The estimated Net Worth of Kevin Ctang Capital Partner... is at least $14.3 millió dollars as of 27 November 2018. Kevin Partner owns over 3,063 units of Odonate Therapeutics Inc stock worth over $14,271,419 and over the last 7 years Kevin sold ODT stock worth over $0.

Kevin Partner ODT stock SEC Form 4 insiders trading

Kevin has made over 16 trades of the Odonate Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Kevin bought 3,063 units of ODT stock worth $47,905 on 27 November 2018.

The largest trade Kevin's ever made was buying 1,291,666 units of Odonate Therapeutics Inc stock on 7 December 2017 worth over $30,999,984. On average, Kevin trades about 114,479 units every 22 days since 2017. As of 27 November 2018 Kevin still owns at least 12,742,338 units of Odonate Therapeutics Inc stock.

You can see the complete history of Kevin Partner stock trades at the bottom of the page.



What's Kevin Partner's mailing address?

Kevin's mailing address filed with the SEC is 9500 Gilman Dr, La Jolla, CA 92093, USA.

Insiders trading at Odonate Therapeutics Inc

Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis és Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.



What does Odonate Therapeutics Inc do?

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.



What does Odonate Therapeutics Inc's logo look like?

Odonate Therapeutics Inc logo

Complete history of Kevin Partner stock trades at Odonate Therapeutics Inc

Dátum
#
Cég
Az érdekelt
Trans.
Tranzakció
Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
27 Nov 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 3,063 $15.64 $47,905
27 Nov 2018
12,742,338
21 Nov 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 16,937 $15.29 $258,967
21 Nov 2018
12,739,275
1 Nov 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 10,000 $14.87 $148,700
1 Nov 2018
12,722,338
26 Oct 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 10,235 $14.98 $153,320
26 Oct 2018
12,712,338
23 Oct 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 39,765 $15.35 $610,393
23 Oct 2018
12,702,103
27 Sep 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 40,000 $19.16 $766,400
27 Sep 2018
12,662,338
24 Sep 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 40,000 $19.75 $790,000
24 Sep 2018
12,622,338
18 Sep 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 90,000 $19.55 $1,759,500
18 Sep 2018
12,582,338
21 Aug 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 7,505 $19.47 $146,122
21 Aug 2018
12,492,338
16 Aug 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 49,685 $19.49 $968,361
16 Aug 2018
12,484,833
13 Aug 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 22,810 $18.93 $431,793
13 Aug 2018
12,435,148
28 Feb 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 14,050 $27.42 $385,251
28 Feb 2018
12,412,338
23 Feb 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 28,612 $27.42 $784,541
23 Feb 2018
12,398,288
20 Feb 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 39,083 $27.17 $1,061,885
20 Feb 2018
12,369,676
14 Feb 2018 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 128,255 $22.47 $2,881,890
14 Feb 2018
12,330,593
7 Dec 2017 Kevin Ctang Capital Partner...
Chief Executive OfficerChief Operating Officer
Megvenni 1,291,666 $24.00 $30,999,984
7 Dec 2017
12,202,338


Odonate Therapeutics Inc executives and stock owners

Odonate Therapeutics Inc executives and other stock owners filed with the SEC include: